Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE

INTRODUCTION: Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatelet therapy, have been excluded from clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolonics-Farkas, Abigél M., Šterclová, Martina, Mogulkoc, Nesrin, Kus, Jan, Hájková, Marta, Müller, Veronika, Jovanovic, Dragana, Tekavec-Trkanjec, Jasna, Littnerová, Simona, Hejduk, Karel, Vašáková, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497686/
https://www.ncbi.nlm.nih.gov/pubmed/32734423
http://dx.doi.org/10.1007/s40264-020-00978-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497686/
https://www.ncbi.nlm.nih.gov/pubmed/32734423
http://dx.doi.org/10.1007/s40264-020-00978-5

Ejemplares similares